Stocks Health care AIDX
NASDAQ · Health care20/20 Biolabs, Inc. (AIDX)
20/20 Biolabs, Inc. reported revenue of $2M in fiscal 2025, up 16.7% from a year earlier. It posted a net loss of $3.7M. At June 30, 2026 it held $4.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
Key facts about 20/20 Biolabs, Inc.
- Net worth
- 20/20 Biolabs, Inc. has a market value (market cap) of $2.5M at the latest share price, and shareholders' equity of $1.6M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $2M (+16.7% year on year), with a net loss of $3.7M.
- Cash flow
- In fiscal 2025 operations used $1.9M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 14, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- 20/20 Biolabs, Inc.'s next report was expected around October 26, 2026 and is not on file with the SEC yet.
What 20/20 Biolabs, Inc. does
20/20 Biolabs, Inc. is registered with the SEC under industry code SIC 8734 (Services-Testing Laboratories). Its shares trade on NASDAQ under the ticker AIDX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $2M | -$3.7M | -$0.76 | n/a |
| 2025 | $1.8M | -$5.6M | -$1.16 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where AIDX ranks in Health care
Latest SEC filings
What 20/20 Biolabs, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 6, 2026Preliminary proxy statement PRE 14A
- September 18, 2026
- September 10, 2026
- September 2, 2026
- August 19, 2026Additional proxy material DEFA14A
- August 19, 2026
- August 17, 2026
- August 14, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 37% to $730.6K versus the same quarter last year; diluted EPS -$0.26 versus -$0.17.
- August 5, 2026
- July 22, 2026
Insider trades
What the people running 20/20 Biolabs, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| February 19, 2026 | Cohen Richard MDirector | Exercised options | 7,700 | - |
| February 19, 2026 | Compton John G.Director | Exercised options | 7,669 | - |
| February 19, 2026 | Ross Michael A.Director | Exercised options | 31 | - |
| February 19, 2026 | Rollins John WoodsonDirector | Exercised options | 13,029 | - |
| February 19, 2026 | Rollins John WoodsonDirector | Exercised options | 6,135 | - |
Who owns AIDX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Jonathan M Cohen13D, may seek influence | 16.8% | March 10, 2026 |
| Streeterville Capital LLC13G, passive with 2 related filers | 9.9% | February 25, 2026 |
| Full Succeed International Limited13G, passive with 2 related filers | 6.3% | March 10, 2026 |
Largest institutional holders
Insiders
4 insiders reported holding 52,341 shares in total, about $11.8K at the last price.
| Holder | Shares |
|---|---|
| Rollins John WoodsonDirector | 30,275 |
| Compton John G.Director | 14,335 |
| Cohen Richard MDirector | 7,700 |
| Ross Michael A.Director | 31 |
Questions about AIDX
What does 20/20 Biolabs, Inc. do?
20/20 Biolabs, Inc. is a company in the Health care sector, listed on NASDAQ as AIDX. Its shares trade on NASDAQ under the ticker AIDX.
What is 20/20 Biolabs, Inc.'s net worth?
20/20 Biolabs, Inc. has a market value (market cap) of $2.5M at the latest share price, and shareholders' equity of $1.6M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is 20/20 Biolabs, Inc. profitable?
No. In fiscal 2025 it reported a net loss of $3.7M on revenue of $2M.
How much revenue does 20/20 Biolabs, Inc. make?
In fiscal 2025 20/20 Biolabs, Inc. reported revenue of $2M. That is 16.7% more than a year earlier.
When did 20/20 Biolabs, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the preliminary proxy statement from October 6, 2026.
When is 20/20 Biolabs, Inc.'s next earnings report?
20/20 Biolabs, Inc.'s next report was expected around October 26, 2026 and is not on file with the SEC yet.
Similar companies
Compare AIDX with
Follow AIDX
Get an email when 20/20 Biolabs, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values 20/20 Biolabs, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.